Breaking News
Advanced Instruments Acquires SAL Scientific, Expertise, and a Range of Cell Growth Supplements in Support of Research & Drug Discovery Workflows
Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the acquisition of SAL Scientific Ltd., a private company that develops and manufactures a portfolio of cell growth supplements for Chinese Hamster Ovary (CHO) and Human Embryonic Kidney (HEK) cells. These reagents substantially improve cell growth under stressful conditions and help accelerate cell line development (CLD) biology workflows to maximize biotherapeutic production. The acquisition expands Advanced Instruments’ reagent expertise and furthers its commitment to bioprocess workflows for advanced therapies.
SAL Scientific is the developer and manufacturer of the InstiGRO™, InstiSHAKE™, and InstiTHAW™ Cell Growth Supplements that Advanced Instruments exclusively distributes today. As part of Advanced Instruments’ Solentim portfolio, these reagents are utilized in the early stages of biologic drug development to accelerate the selection of optimal clones for production of monoclonal antibodies and viral vectors used in gene therapies. Acquiring SAL Scientific’s expertise will support the expansion of reagent technologies and deliver additional in-house capabilities that support ongoing technology adoption, new product innovation and enhanced customer support.
“The addition of SAL Scientific aligns with our core strategy to invest in leading technologies that deliver significant customer value across the cell line development workflow,” commented Byron Selman, President & CEO of Advanced Instruments. “With SAL Scientific, we are investing to support customers in these workflows with these cell culture media supplements that provide improved cell growth, colony formation and cloning efficiency.”
“We are excited about joining the Advanced Instruments team,” said Steve Game, Founding Director of SAL Scientific. “As an existing commercial partner, we recognize the strong synergy between the Insti supplements and the Advanced Instruments cell line development systems. We are confident about the value that Advanced Instruments will add with regard to infrastructure for innovative product development, manufacturing capacity and global commercial reach and that this combination will continue to accelerate growth for the Insti products.”
“We look forward to SAL Scientific joining the Advanced Instruments and Patricia Industries family and continuing on the next phase of growth together,” said Yuriy Prilutskiy, Head of Patricia Industries North America, a part of Investor AB, and owner of Advanced Instruments. “Patricia Industries is committed to continuing our support of Advanced Instruments in their mission to deliver solutions that accelerate and improve the development of biopharmaceuticals globally, and we are excited to further increase investment in building Advanced Instruments’ portfolio of CLD products.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more